WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004009588) BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/009588    International Application No.:    PCT/IB2003/003155
Publication Date: 29.01.2004 International Filing Date: 07.07.2003
Chapter 2 Demand Filed:    22.09.2003    
IPC:
A61K 31/46 (2006.01), A61K 31/538 (2006.01), A61K 31/55 (2006.01), C07D 451/04 (2006.01), C07D 451/06 (2006.01), C07D 451/14 (2006.01)
Applicants: PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US) (For All Designated States Except US).
BLUMBERG, Laura, Cook [US/US]; (US) (For US Only).
BROWN, Matthew, Frank [US/US]; (US) (For US Only).
HAYWARD, Matthew, Merrill [US/US]; (US) (For US Only).
POSS, Christopher, Stanley [US/US]; (US) (For US Only)
Inventors: BLUMBERG, Laura, Cook; (US).
BROWN, Matthew, Frank; (US).
HAYWARD, Matthew, Merrill; (US).
POSS, Christopher, Stanley; (US)
Agent: LUMB, J., Trevor; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US)
Priority Data:
60/397,263 18.07.2002 US
Title (EN) BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR
(FR) DERIVES DE PIPERIDINE BICYCLIQUES UTILISES COMME ANTAGONISTES DU RECEPTEUR DE CHIMIOKINE CCR1
Abstract: front page image
(EN)A compound of the formula (I) wherein a, b, cR1, R2, R3, R4, R5, R6, Q, W, Y, and Z are defined as above, useful as potent and selective inhibitors of MIP-1&agr;(CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
(FR)L'invention concerne un composé représenté par la formule (I) dans laquelle a, b, c, R1, R2, R3, R4, R5, R6, Q, W, Y, et Z sont tels que définis dans le descriptif. Ce composé est indiqué en tant qu'inhibiteur puissant et sélectif de la liaison de MIP-1$g(a)(CCL3) avec son récepteur CCR1 présent sur les cellules inflammatoires et immunomodulatrices (de préférence leucocytes et lymphocytes).
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)